Following this activity, participants should be able to: (1) Integrate recent advances and available clinical data to optimally select and sequence agents based on HR/HER2-status and biomarkers; (2) Discuss new therapies available for metastatic breast cancer; and (3) Describe common issues faced by survivors living with metastatic breast cancer.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 3025 Chemical Road
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedOct 29, 2025
-
Last day to claim creditOct 16, 2026 5 days left
-
Physicians’ Education Resource The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing
-
EfficientCME, CME Outfitters, LLC From Data to Decisions: An Integrated CME Activity Designed to Assess and Compare the Practice Patterns of Specialists and General Oncologists Related to the Management of HER2-Negative Metastatic Breast Cancer
-
PRIME Education, Inc. (PRIME®) Applying Frontline and Maintenance Evidence to Clinical Scenarios in Metastatic HER2+ Breast Cancer: A Case Panel Discussion
-
National Comprehensive Cancer Network Recorded Presentation from the NCCN 2026 Annual Conference: Breast Cancer Case Review
-
National Comprehensive Cancer Network Archived NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer
-
National Comprehensive Cancer Network Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer
